IMS-001 is under clinical development by Imstem Biotechnology and currently in Phase II for Secondary Progressive Multiple Sclerosis (SPMS). According to GlobalData, Phase II drugs for Secondary Progressive Multiple Sclerosis (SPMS) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMS-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMS-001 overview

IMS-001 is under development for the treatment of relapsing-remitting, secondary, and primary progressive forms of multiple sclerosis including neuromyelitis optica spectrum disorder (NMOSD), type 1 diabetes mellitus, acute and chronic GVHD, inflammatory bowel disease, stroke, adrenoleukodystrophy, Duchenne muscular dystrophy, Parkinson's disease unspecified indication. The drug candidate is administered through parenteral and intravenous route. It is a stem cell therapy based on hES-MSCs which includes human embryonic stem cells (hESC) derived mesenchymal stem cells (MSCs). It is developed based on T-MSC platform. It was also under development for the treatment of spinal cord injury, ARDS due to COVID-19 disease.

For a complete picture of IMS-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.